MX9705697A - Metodos para reducir los niveles de calcio del suero. - Google Patents

Metodos para reducir los niveles de calcio del suero.

Info

Publication number
MX9705697A
MX9705697A MX9705697A MX9705697A MX9705697A MX 9705697 A MX9705697 A MX 9705697A MX 9705697 A MX9705697 A MX 9705697A MX 9705697 A MX9705697 A MX 9705697A MX 9705697 A MX9705697 A MX 9705697A
Authority
MX
Mexico
Prior art keywords
calcium levels
serum calcium
methods
decreasing serum
decreasing
Prior art date
Application number
MX9705697A
Other languages
English (en)
Other versions
MXPA97005697A (es
Inventor
Susan Margaret Boss
Willard Honglen Dere
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9705697A publication Critical patent/MX9705697A/es
Publication of MXPA97005697A publication Critical patent/MXPA97005697A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a un método para reducir los niveles de calcio del suero, que comprende la administracion a un ser humano que tenga la necesidad del mismo, de un compuesto que tiene la formula (I), en donde R1 y R3 son independientemente hidrogeno, -CH3, (a), o (b), en donde Ar es fenilo substituido opcionalmente; R2 se selecciona del grupo que consiste de pirrolidina, hexametilenimino, y piperidino; o una sal o solvato del mismo aceptable farmacéuticamente.
MXPA/A/1997/005697A 1995-01-30 1997-07-28 Metodos para reducir los niveles de calcio del suero MXPA97005697A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/380,881 US5512583A (en) 1995-01-30 1995-01-30 Methods of decreasing serum calcium levels
US08380881 1995-01-30
PCT/US1996/001406 WO1996023501A1 (en) 1995-01-30 1996-01-29 Methods of decreasing serum calcium levels

Publications (2)

Publication Number Publication Date
MX9705697A true MX9705697A (es) 1997-10-31
MXPA97005697A MXPA97005697A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
UA43389C2 (uk) 2001-12-17
CZ286161B6 (cs) 2000-01-12
AU4862296A (en) 1996-08-21
ES2172633T3 (es) 2002-10-01
AU701262B2 (en) 1999-01-21
DK0723780T3 (da) 2002-06-17
US5512583A (en) 1996-04-30
JPH10513184A (ja) 1998-12-15
RU2176503C2 (ru) 2001-12-10
CN1086943C (zh) 2002-07-03
NO973470D0 (no) 1997-07-28
DE69620661T2 (de) 2002-11-14
NO973470L (no) 1997-07-28
PT723780E (pt) 2002-08-30
EP0723780A2 (en) 1996-07-31
CZ240397A3 (cs) 1998-01-14
WO1996023501A1 (en) 1996-08-08
ATE216232T1 (de) 2002-05-15
HUP9801335A3 (en) 2000-03-28
HUP9801335A2 (hu) 1999-05-28
EP0723780B1 (en) 2002-04-17
NZ302546A (en) 2000-06-23
DE69620661D1 (de) 2002-05-23
CA2211530A1 (en) 1996-08-08
KR19980701731A (ko) 1998-06-25
EP0723780A3 (es) 1996-09-11
CN1172432A (zh) 1998-02-04

Similar Documents

Publication Publication Date Title
AU8155894A (en) Methods of inhibiting thrombin
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
AU7583494A (en) Methods of inhibiting uterine fibrosis
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees